Abstract:Abstract Background Therapeutic lymphangiogenesis in an orthotopic lung transplant model has been shown to improve acute allograft rejection that is mediated at least in part through hyaluronan drainage. Lymphatic vessel endothelial hyaluronan receptor (LYVE-1) expressed on the surface of lymphatic endothelial cells plays important roles in hyaluronan uptake. The impact of current immunosuppressive therapies on lung lymphatic endothelial cells is largely unknown. We tested the hypothesis that FK506, the most commonly used immunosuppressant after lung transplantation, induces lung lymphatic endothelial cell dysfunction. Methods Lung lymphatic endothelial cells were cultured in vitro and treated with FK506. Telomerase activity was measured using the TRAP assay. Protein expression of LYVE-1 and senescence markers p21 and β-galactosidase was assessed with western blotting. Matrigel tubulation assay were used to investigate the effects of FK506 on TNF-α-induced lymphangiogenesis. Dual luciferase reporter assay was used to confirm NFAT-dependent transcriptional regulation of LYVE-1. Flow cytometry was used to examine the effects of FK506 on LYVE-1 in precision-cut-lung-slices ex vivo and on hyaluronan uptake in vitro . Results In vitro , FK506 downregulated telomerase reverse transcriptase expression, resulting in decreased telomerase activity and subsequent induction of p21 expression and cell senescence. Treatment with FK506 decreased LYVE-1 mRNA and protein levels and resulted in decreased LEC HA uptake. Similar result showing reduction of LYVE-1 expression when treated with FK506 was observed ex vivo . We identified a putative NFAT binding site on the LYVE-1 promoter and cloned this region of the promoter in a luciferase-based reporter construct. We showed that this NFAT binding site regulates LYVE-1 transcription, and mutation of this binding site blunted FK506-dependent downregulation of LYVE-1 promoter-dependent transcription. Finally, FK506-treated lymphatic endothelial cells show a blunted response to TNF-α-mediated lymphangiogenesis. Conclusion FK506 alters lymphatic endothelial cell molecular characteristics and causes lymphatic endothelial cell dysfunction in vitro and ex vivo. These effects of FK506 on lymphatic endothelial cell may impair the ability of the transplanted lung to drain hyaluronan macromolecules in vivo . The implications of our findings on the long-term health of lung allografts merit more investigation.

FKBP12 is the only FK506 binding protein mediating T-cell inhibition by the immunosuppressant FK506

FK506 binding protein 12 mediates sensitivity to both FK506 and rapamycin in murine mast cells

Effect of a new immunosuppressive agent, FK506, on human lymphocyte responses in vitro. II. Inhibition of the production of IL-2 and gamma-IFN, but not B cell-stimulating factor 2.

Mechanism of TGFβ Receptor Inhibition by FKBP12

Three-dimensional Structure of Human FKBP52

EFFECT OF A NEW IMMUNOSUPPRESSIVE AGENT, FK506, ON HUMAN LYMPHOCYTE RESPONSES IN VITRO: I. Inhibition of Expression of Alloanticen‐Activated Suppressor Cells, As Well As Induction of Alloreactivity

Research Progress of FKBPs

Comparative analysis of FKBP family protein: evaluation, structure, and function in mammals and Drosophila melanogaster

Acute Influence of FK506 on T-Lymphocyte Populations of Peripheral Blood and Spleen in Rats

Binding Modes and Conformational Changes of FK506-binding Protein 51 Induced by Inhibitor Bindings: Insight into Molecular Mechanisms Based on Multiple Simulation Technologies

FK506-Binding Protein 11 Is a Novel Plasma Cell-Specific Antibody Folding Catalyst with Increased Expression in Idiopathic Pulmonary Fibrosis

[Study on the Effect of Immunosuppressive Agent FK506 on Growth and Migration of Lung Cancer Cell].

Regulation of steroid hormone receptor function by the 52-kDa FK506-binding protein (FKBP52)

Distribution and Protein Binding of FK506, a Potent Immunosuppressive Macrolide Lactone, in Human Blood and Its Uptake by Erythrocytes

FKBP12 is a critical regulator of the heart rhythm and the cardiac voltage-gated sodium current in mice

FK506 induces lung lymphatic endothelial cell senescence and downregulates LYVE-1 expression, with associated decreased hyaluronan uptake

Plasticity of Treg and imbalance of Treg/Th17 cells in patients with systemic sclerosis modified by FK506

Overexpressed FKBP5 mediates colorectal cancer progression and sensitivity to FK506 treatment via the NF‐κB signaling pathway

3 D Structure of Human FK 506-Binding Protein 52 : Implications for the Assembly of the Glucocorticoid Receptor Hsp 90 Immunophilin Heterocomplex

FK506 promotes liver regeneration by suppressing natural killer cell activity

Role of FK506 Binding Protein on Tacrolimus Distribution in Red Blood Cells